A 68-year-old male non-smoker presents with 9 months of progressive exertional dyspnea and dry cough. HRCT shows basal, subpleural honeycombing with traction bronchiectasis in a usual interstitial pneumonia (UIP) pattern. Spirometry reveals FVC 62% predicted and FEV₁/FVC 0.85; DLCO is 38% predicted. IPF is diagnosed and the GAP Index is calculated: Gender (Male = 1) + Age 68 years (1 point) + FVC 62% (1 point) + DLCO 38% (1 point) = 4 points total. The patient is stratified into the category marked **B** in the diagram. Which of the following best describes the prognostic significance and recommended management approach for a patient in this GAP stage?

Question

Accepted Answer

A. Approximately 16% one-year mortality; antifibrotic therapy (pirfenidone or nintedanib) is indicated, with lung transplant evaluation reserved for Stage III progression. ## Why option 1 is correct

The patient's GAP score of 4 places him in **GAP Stage II** (score range 4–5), marked as **B** in the diagram. According to the Ley et al. (2012) GAP Index stratification, Stage II carries approximately 16% one-year mortality and 42% three-year mortality. Management for Stage II IPF includes initiation of antifibrotic therapy (pirfenidone or nintedanib), both of which slow FVC decline by approximately 50%. Lung transplant evaluation is reserved for Stage III (6–8 points, 39% one-year mortality) or for Stage II patients with rapid functional decline (≥10% FVC drop or ≥15% DLCO drop over 6–12 months). This approach aligns with current ATS/ERS/JRS/ALAT IPF Guidelines 2024, which recommend early antifibrotic therapy and risk-stratified transplant referral based on GAP staging and longitudinal change.

## Why each distractor is wrong

- **Option 2**: This describes GAP Stage I (0–3 points, ~6% one-year mortality), not Stage II. Moreover, corticosteroids and immunosuppressive therapy are contraindicated in IPF; the PANTHER-IPF trial demonstrated harm with this approach and these agents should be avoided.
- **Option 3**: This describes GAP Stage III (6–8 points, ~39% one-year mortality), not Stage II. Urgent transplant evaluation is appropriate for Stage III, not Stage II, unless rapid decline occurs.
- **Option 4**: The one-year mortality estimate of 25% does not correspond to any GAP stage, and observation alone without antifibrotic therapy is not evidence-based; both pirfenidone and nintedanib have demonstrated slowing of FVC decline in IPF.

**High-Yield:** GAP Stage II (score 4–5) = ~16% one-year mortality; initiate antifibrotic therapy and reassess every 6–12 months; transplant evaluation triggered by Stage III or rapid functional decline (≥10% FVC or ≥15% DLCO drop).

[cite: Ley B et al. Ann Intern Med 2012; ATS/ERS/JRS/ALAT IPF Guidelines 2024]

Answer

B. Approximately 6% one-year mortality; corticosteroid and immunosuppressive therapy is first-line to slow disease progression

Answer

C. Approximately 25% one-year mortality; observation alone is recommended as antifibrotic agents have not shown mortality benefit in this stage

Answer

D. Approximately 39% one-year mortality; urgent lung transplant evaluation should be initiated immediately regardless of functional status

Explanation

Why option 1 is correct

Why each distractor is wrong

Practice similar questions